CORMEDIX INC(NASDAQ:CRMD) stock News

CRMD Latest News, Press Relases and Analysis

All

Press Releases

18 days ago - By: Chartmill

CorMedix Inc (NASDAQ:CRMD) Identified as a Top Growth Stock Candidate

18 days ago - By: CorMedix, Inc.

CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

a month ago - By: Zacks Investment Research - Mentions: NVS INCY ANIP

INCY Announces New Late-Stage Data on Skin Disease Drug

a month ago - By: Zacks Investment Research - Mentions: PBYI ANIP

PBYI Surges 30% in 3 Months: How Should You Play the Stock?

a month ago - By: Zacks Investment Research - Mentions: PFE AMPH

CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock?

a month ago - By: Zacks Investment Research - Mentions: ZTS KNSA PHAR

Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain

a month ago - By: Benzinga

Analyst Expectations For Cormedix's Future

a month ago - By: Zacks Investment Research - Mentions: RARE KNSA PHAR

RARE Reports Positive Long-Term Data From Metabolic Disorder Study

a month ago - By: Zacks Investment Research

CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

a month ago - By: CorMedix, Inc.

CorMedix Announces Strategic Minority Investment in Talphera

a month ago - By: Talphera, Inc. - Mentions: TLPH

Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market

a month ago - By: Zacks Investment Research - Mentions: KNSA IMVT PHAR

IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results

a month ago - By: Zacks Investment Research - Mentions: BMY CYTK KNSA

Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results

a month ago - By: Zacks Investment Research

Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet

a month ago - By: Zacks Investment Research - Mentions: EDIT KNSA PHAR

Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol

a month ago - By: Benzinga - Mentions: CYTK BMY HUM NVO ...

10 Health Care Stocks Whale Activity In Today's Session

a month ago - By: Zacks Investment Research - Mentions: PFE AMPH

Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path?

a month ago - By: CorMedix, Inc.

CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team

2 months ago - By: Zacks Investment Research - Mentions: ALNY KNSA

ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win

2 months ago - By: Zacks Investment Research - Mentions: BIIB LLY ANIP

Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi

2 months ago - By: Zacks Investment Research - Mentions: JNJ ANIP

J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure

2 months ago - By: Zacks Investment Research - Mentions: KNSA OTLK PHAR

OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug

2 months ago - By: Yahoo Finance

CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio

2 months ago - By: Zacks Investment Research - Mentions: INO KNSA PGEN

INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug

2 months ago - By: CorMedix, Inc.

CorMedix to Participate in Upcoming Investor Conferences

2 months ago - By: Zacks Investment Research - Mentions: CPRX KNSA PHAR

Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin

2 months ago - By: Zacks Investment Research - Mentions: MRK ANIP IOVA

IOVA Stock Drops 6% on $350M Common Stock Offering

2 months ago - By: Zacks Investment Research - Mentions: GILD CVS ANIP

GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo

2 months ago - By: Zacks Investment Research - Mentions: ADAG

Is Adagene (ADAG) Outperforming Other Medical Stocks This Year?

2 months ago - By: Zacks Investment Research

Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade